New Trump Admin Could Drastically Change Research on Infectious Diseases

For decades now, the National Institutes of Health has funded a lot of research on illnesses and vaccines, allowing researchers to run different clinical trials and develop treatments to save millions of lives. Grants from this agency are awarded to almost every state, supporting thousands of jobs countrywide. In 2023, almost $5 billion of the agency’s budget was awarded to organizations outside the institute in America to advance careers in science as well as medicine.

The National Institute of Allergy and Infectious Disease, a major division of this agency, has seen cures for hepatitis C being developed, a vaccine for RSV being formulated, and even lifesaving HIV treatments. The division also supports scientists globally, ensuring that America maintains a prominent role in global discussions about biosecurity.

During the coronavirus pandemic, this division led the containment response, with former director Dr. Anthony Fauci recommending that schools be closed countrywide and people wear face masks. This raised concerns as well as fueled opposition from some legislators, with GOP members in Congress going as far as to investigate the body’s work, reducing its budget and proposing that the agency be overhauled.

Recently, President Trump nominated Robert F. Kennedy Jr. to run the Department of Health and Human Services, which oversees the National Institutes of Health. Following his nomination, Kennedy announced that he wanted to change the focus of research from vaccines and infectious illnesses, the literal core of the National Institute of Allergy and Infectious Diseases’ mission to comprehend, treat and prevent allergic, immunologic, and infectious illnesses.

This is in addition to wanting to fire and replace some of the agency’s employees, arguing that a chunk of the National Institutes of Health budget needed to center on holistic, alternative, and preventative approaches to health.

Dr. Jay Bhattacharya, who was also appointed recently by Trump to lead the National Institutes of Health, has focused on researching health policy issues during his career. He has also carried out research on the agency, noting that while it did finance a lot of new and innovative research, more could be done.

While many agree that some reforms would do the agency some good, patient advocates and experts argue that dismantling or overhauling the National Institute of Allergy and Infectious Diseases without properly understanding the important work it does could endanger the country’s standing as a pioneer in biomedical innovation as well as the development of future lifesaving treatments.

If the new administration in Washington shifts the government position on infectious diseases research, it may be up to companies like Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) to carry the mantle of developing new immunotherapy treatments against these diseases whose prevalence seems to be growing with each passing year.

NOTE TO INVESTORS: The latest news and updates relating to Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) are available in the company’s newsroom at https://ibn.fm/SCNI

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN